Autres langues Annexin Pharmaceuticals AB

Actions

ANNX

SE0025159387

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 23/09/2026			Varia. 5j.	Varia. 1 janv.
9,900 ^SEK	-2,46%		-21,12%	-50,00%

22/09	16 actions ont jusqu’ici inscrit aujourd’hui un nouveau plus bas sur 52 semaines à la Bourse de Stockholm	FW
17/09	Annexin Pharmaceuticals traite un premier patient dans le cadre de l'extension de son essai sur l'occlusion de la veine rétinienne	MT

Autres langues

17/09	Annexin Pharmaceuticals Doses First Patient in Expanded Retinal Vein Occlusion Trial
17/09	First patient treated with vanexin following anti-VEGF injection in the NEXUS study
17/09	Annexin Pharmaceuticals AB Treats First Patient With Vanexin Following Anti-VEGF Injection In The NEXUS Study
10/09	Annexin Pharmaceuticals to Present at Investing in Life Science on September 22
21/08	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
21/08	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate
21/08	Annexin advances the NEXUS study to include patients who received an anti-VEGF injection
21/08	Annexin Pharmaceuticals Advances the Nexus Study to Include Patients Who Received an Anti-Vegf Injection
20/08	Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV
20/08	Annexin Pharmaceuticals AB Receives The International Nonproprietary Name Vanexin For The Drug Candidate ANXV
21/07	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study
21/07	Annexin updates on nine patients treated in NEXUS study
03/07	Annexin's rights issue 98 percent subscribed
23/06	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO
23/06	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo
15/06	The subscription period in Annexin Pharmaceuticals’ rights issue begins today
10/06	Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue
05/06	Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10
03/06	Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million
21/05	Annexin investigates a three-day ANXV treatment regimen in patients with RVO
21/05	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo
11/05	Annexin receives German approval for ANXV clinical trial
11/05	Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study
11/05	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study
24/04	Annexin Pharmaceuticals (Q1 review): Study on track